Reviva Pharma Prices $10 Mln Public Offering Of Shares And Series G And H Warrants; Stock Down

Reviva Pharmaceuticals priced a public offering of 6.66 million shares alongside series G warrants exercisable for up to 6.66 million shares; details on series H warrants were truncated in the report. This is a dilutive equity capital raise that will increase share count and could put modest downward pressure on the stock, but the news is company-specific and likely of limited market-wide impact.

Analysis

Reviva Pharmaceuticals priced a public offering of 6.66 million shares alongside series G warrants exercisable for up to 6.66 million shares; details on series H warrants were truncated in the report. This is a dilutive equity capital raise that will increase share count and could put modest downward pressure on the stock, but the news is company-specific and likely of limited market-wide impact.